Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863338 | 1.00 | PARP1 (0.92) | PARP1LMNA | |
| SCHEMBL3388183 | 0.96 | PARP1 (1.00) | PARP1 | |
| SCHEMBL3385144 | 0.91 | PARP1 (0.80) | PARP1LMNA | |
| SCHEMBL3388610 | 0.89 | PARP1 (1.00) | PARP1 | |
| SCHEMBL3385663 | 0.87 | PARP1 (0.77) | PARP1LMNA | |
| SCHEMBL13007107 | 0.86 | PARP1 (0.70) | PARP1LMNA | |
| SCHEMBL30132754 | 0.86 | PARP1 (0.73) | PARP1LMNA | |
| SCHEMBL25890317 | 0.86 | PARP1 (0.73) | PARP1LMNA | |
| SCHEMBL4440678 | 0.86 | PARP1 (0.79) | PARP1 | |
| SCHEMBL13007009 | 0.86 | PARP1 (0.72) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025227060-A1 | HETEROCYCLIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) IN COMBINATION WITH ADDITIONAL AGENTS FOR USE IN THE TREATMENT OF CANCER | INSILICO MEDICINE IP LIMITED (CN) | 2025-10-30 | — | — | WO | disclosed |
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4554683-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | Lantern Pharma Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-118973617-A | Conjugates, compositions, and methods of use | 维尔托索宾科公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-4460330-A1 | CONJUGATES, COMPOSITIONS AND METHODS OF USE | Virtuoso Binco, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240245643-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-25 | — | — | US | disclosed |
| EP-4376822-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024016014-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023131219-A1 | CONJUGATES, COMPOSITIONS AND METHODS OF USE | VIRTUOSO BINCO, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023010119-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20220257777-A1 | HSP90-BINDING CONJUGATES AND COMBINATION THERAPIES THEREOF | TVA (ABC), LLC | 2022-08-18 | — | — | US | disclosed |
| US-11364241-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | MEDIVATION TECHNOLOGIES LLC (US) | 2022-06-21 | — | — | US | disclosed |
| EP-3989980-A1 | HSP90-BINDING CONJUGATES AND COMBINATION THERAPIES THEREOF | Tarveda Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114126624-A | HSP90 binding conjugates and combination therapies thereof | 塔弗达治疗有限公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | PARP1, PARP2, PARP3 | PARP1 1/4885LMNA 768/4885 |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | PARP1, PARP2, PARP11 | PARP1 1/4885LMNA 730/4885 |
| US-11364241-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | PARP1, PARP2, PARP11 | PARP1 1/4885LMNA 164/4885 |
| US-20240245643-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | PARP2, MRE11, PARP1 | PARP1 3/4885LMNA 1800/4885 |
| US-20220257777-A1 | HSP90-BINDING CONJUGATES AND COMBINATION THERAPIES THEREOF | HSP90B1, HSP90AB1, HSP90AB2P | PARP1 1839/4885LMNA 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.